BeStock  
Stocks › Biotechnology › VRDN

Viridian Therapeutics VRDN

US equityMarket cap rank #2344Biotechnology
$29.96 −$1.48 (-4.71%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $29.96 0.00%
Open$31.12
Prev close$31.44
Day range$29.87 – $31.75
Volume1.75M
Market cap$3.40B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$25.75M-63.5% YoY
Operating profit-$103.48M-158.6% YoY
Net profit-$101.21M-192.5% YoY
Diluted EPS-$0.81-138.2% YoY
Free cash flow-$103.14M-21.7% YoY
Operating cash flow-$92.77M

Revenue, last 8 quarters

$72.0KDec '24$72.0KMar '25$75.0KJun '25$70.6MSep '25$132.0KDec '25$141.0KMar '26$284.0KJun '26$25.8MSep '26

Net profit, last 8 quarters

$-79.7MDec '24$-86.9MMar '25$-100.7MJun '25$-34.6MSep '25$-120.4MDec '25$-104.9MMar '26$-127.1MJun '26$-101.2MSep '26

Diluted EPS by quarter

-0.81Dec '24-0.87Mar '25-1.00Jun '25-0.34Sep '25-1.08Dec '25-0.90Mar '26-1.05Jun '26-0.81Sep '26

Free cash flow by quarter

$-73.4MDec '24$-92.7MMar '25$-75.4MJun '25$-84.7MSep '25$-24.0MDec '25$-119.7MMar '26$-106.6MJun '26$-103.1MSep '26

Annual revenue

$1.1MFY20$3.0MFY21$1.8MFY22$314.0KFY23$302.0KFY24$70.8MFY25

Profitability & balance sheet

Gross margin94.1%
Operating margin-1,781.4%
Net margin-1,741.9%
Return on equity-115.0%
Return on assets-57.1%
Return on invested capital-88.1%
Current ratio14.46
Liabilities / assets43.5%
Cash & investments$955.21M
Total debt$242.46M
Net cash (debt)$712.75M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $25.75M $284,000.00 $141,000.00 $70.85M $132,000.00
Total Operating Revenue $25.75M $284,000.00 $141,000.00 $70.85M $132,000.00
Cost of Revenue $1.53M – – – –
Gross Profit $24.23M – – – –
Operating Expense $127.70M $126.55M $116.31M $434.24M $122.88M
Selling and Admin Expenses $57.61M $54.98M $38.68M $95.32M $33.67M
-General & Admin Expense $57.61M $54.98M $38.68M $95.32M $33.67M
Research & Development $70.09M $71.58M $77.63M $338.93M $89.21M
Operating Profit -$103.48M -$126.27M -$116.17M -$363.40M -$122.75M
Net Non-Operating Interest Income (Expense) $264,000.00 $183,000.00 $4.41M $22.45M $4.51M
Non-Operating Interest Income $9.54M $8.49M $7.87M $27.40M $7.79M
Non-Operating Interest Expense $9.27M $8.31M $3.46M $4.95M $3.28M
Other Income (Expense) $2.00M -$1.03M $6.86M -$1.66M -$2.12M
Gain on Sale of Security $2.07M -$1.19M $7.53M – –
Other Non-Operating Income (Expenses) -$66,000.00 $156,000.00 -$672,000.00 -$1.66M -$2.12M
Pretax Profit -$101.21M -$127.12M -$104.90M -$342.60M -$120.36M
Net Profit -$101.21M -$127.12M -$104.90M -$342.60M -$120.36M
Profit from Continuing Operations -$101.21M -$127.12M -$104.90M -$342.60M -$120.36M
Net Income to Parent Company -$101.21M -$127.12M -$104.90M -$342.60M -$120.36M
Other Preferred Stock Dividends -$9.77M – -$12.88M – –
Net Income to Common Stockholders -$91.44M -$127.12M -$92.03M -$342.60M -$161.75M
Basic EPS -$0.81 -$1.05 -$0.90 -$3.32 -$1.08
Diluted EPS -$0.81 -$1.05 -$0.90 -$3.32 -$1.08

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $1.03B $1.10B $789.02M $899.42M $899.42M
Total Current Assets $1.01B $1.08B $784.74M $894.23M $894.23M
Cash and Cash Equivalents & Short-Term Investments $955.21M $981.53M $762.18M $874.65M $874.65M
-Cash and Cash Equivalents $172.86M $164.99M $176.35M $212.38M $212.38M
-Short Term Investments $782.35M $816.54M $585.84M $662.27M $662.27M
Receivables $29.78M $75.00M – – –
-Accounts Receivable $29.78M – – – –
Inventory $85,000.00 – – – –
Restricted Cash $1.30M – – – –
Other Current Assets $26.76M $24.74M $22.56M $19.58M $19.58M
Total Non-Current Assets $15.54M $15.96M $4.27M $5.19M $5.19M
Net PPE $5.62M $4.85M $3.39M $3.65M $3.65M
-Gross PPE $5.62M $4.85M $3.39M $4.87M $4.87M
Goodwill and Other Intangible Assets $9.79M $10.00M – – –
Other Non-Current Assets $131,000.00 $1.11M $888,000.00 $1.54M $1.54M
Total Liabilities $447.97M $435.14M $153.01M $177.25M $177.25M
Total Current Liabilities $70.05M $63.79M $51.81M $70.70M $70.70M
Payables $9.30M $8.65M $13.31M $8.68M $8.68M
-Accounts Payable $9.30M $8.65M $13.31M $8.68M $8.68M
Current Accrued Expenses $37.69M $40.07M $29.12M $41.24M $41.24M
Short-Term Debt and Capital Lease Obligation $806,000.00 $722,000.00 $738,000.00 $753,000.00 $753,000.00
-Current Capital Lease Obligation $806,000.00 $722,000.00 $738,000.00 $753,000.00 $753,000.00
Total Non-Current Liabilities $377.92M $371.34M $101.20M $106.56M $106.56M
Long Term Debt and Capital Lease Obligation $242.46M $242.16M $50.44M $49.94M $49.94M
-Long Term Debt $242.46M $242.16M $50.44M $49.94M $49.94M
Derivative Product Liabilities $11.62M $13.69M $12.50M $20.03M $20.03M
Non-Current Deferred Liabilities $121.61M $113.64M $36.09M $34.24M $34.24M
Other Non-Current Liabilities $2.23M $1.85M $2.18M $2.34M $2.34M
Total Equity $580.70M $662.10M $636.01M $722.17M $722.17M
Stockholders' Equity $580.70M $662.10M $636.01M $722.17M $722.17M
Capital Stock $99.16M $99.16M $133.08M $133.07M $133.07M
-Common Stock $1.14M $1.13M $1.03M $1.02M $1.02M
-Preferred Stock $98.02M $98.02M $132.06M $132.06M $132.06M
Additional Paid-In Capital $2.16B $2.13B $1.95B $1.93B $1.93B
Retained Earnings -$1.67B -$1.57B -$1.44B -$1.34B -$1.34B
Gains/Losses Not Affecting Retained Earnings -$2.20M -$1.15M -$558,000.00 $447,000.00 $447,000.00
-Other Receivables – $75.00M – – –
Current Deferred Liabilities – $181,000.00 $274,000.00 $367,000.00 $367,000.00
-Accumulated Depreciation – – – -$1.22M -$1.22M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$92.77M -$105.32M -$119.65M -$276.39M -$23.75M
Net cash flow from continuing operations -$92.77M -$105.32M -$119.65M -$276.39M -$23.75M
Net Income from Continuing Operations -$101.21M -$127.12M -$104.90M -$342.60M -$120.36M
Gain/Loss from Continuing Operations -$2.41M $5.64M -$7.53M $700,000.00 –
Depreciation & Depletion & Amortization $343,000.00 $117,000.00 $121,000.00 $460,000.00 $120,000.00
Other Non-Cash Items $8.59M $2.34M $2.51M $4.47M $4.20M
Change in Working Capital -$13.76M -$1.84M -$21.39M $23.03M $81.35M
-Change in Prepaid Assets -$1.04M -$2.40M -$2.33M $262,000.00 -$8.59M
-Change in Payables and Accrued Expense $17.31M $909,000.00 -$19.06M $22.77M $19.94M
-Change In Other Working Capital $106,000.00 – – – –
Net cash flow from investing $24.34M -$231.16M $77.26M -$37.56M -$339.42M
Net Cash Flow from Continuing Investing Activities $24.34M -$231.16M $77.26M -$37.56M -$339.42M
Net PPE Purchase and Sale -$370,000.00 -$1.31M -$23,000.00 -$495,000.00 -$240,000.00
Net Investment Purchase and Sale $34.71M -$229.85M $77.28M -$37.07M -$339.18M
Financing Cash Flow $77.61M $325.12M $6.36M $426.74M $405.91M
Net Cash Flow from Continuing Financing Activities $77.61M $325.12M $6.36M $426.74M $405.91M
Net Issuance Payments Of Debt -$250.00M – – $28.88M $28.88M
Net Common Stock Issuance $0.00 $143.75M $0.00 $352.20M $337.29M
Proceeds from Stock Option Exercised $3.63M $1.85M $6.36M $14.79M $8.45M
Net Other Financing Charges $73.98M – – $30.88M $31.30M
Ending Cash Balance $174.16M $164.99M $176.35M $212.38M $212.38M
Net Change in Cash $9.17M -$11.36M -$36.04M $112.79M $42.74M
Beginning Cash Balance $164.99M $176.35M $212.38M $99.59M $169.65M
Free Cash Flow -$103.14M -$106.63M -$119.68M -$276.89M -$23.99M
Net Preferred Stock Issuance – – – $0.00 $0.00

Discussion

No comments yet — be the first to weigh in on VRDN.

Sign in to join the discussion.

Scroll to Top